应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
UPB UpStream Bio Inc.
休市中 07-11 16:00:00 EDT
11.48
-0.36
-3.04%
盘后
11.48
+0.00
0.00%
17:02 EDT
最高
11.85
最低
11.45
成交量
16.50万
今开
11.68
昨收
11.84
日振幅
3.38%
总市值
6.18亿
流通市值
3.59亿
总股本
5,379万
成交额
190.64万
换手率
0.53%
流通股本
3,130万
市净率
1.39
ROE
-28.62%
每股收益
-3.40
52周最高
29.46
52周最低
5.14
市盈率
-3.37
股息
0.00
股息收益率
0.00
ROA
-16.91%
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Upstream Bio, Inc.2025财年第一财季实现净利润-27.27百万美元
市场透视 · 05-11
Upstream Bio, Inc.2025财年第一财季实现净利润-27.27百万美元
单月超6亿美元,医药企业IPO规模重返疫情前水平
财通社 · 2024-11-25
单月超6亿美元,医药企业IPO规模重返疫情前水平
加载更多
公司概况
公司名称:
UpStream Bio Inc.
所属市场:
NASDAQ
上市日期:
2024-10-11
主营业务:
Upstream Bio, Inc.于2021年4月在特拉华州注册成立。他们是一家临床阶段的生物技术公司,开发炎症性疾病的治疗方法,最初专注于严重的呼吸系统疾病。他们正在开发verekitug,这是目前临床开发中唯一已知的拮抗剂,靶向胸腺间质淋巴细胞生成素(“TSLP”)受体,TSLP是一种细胞因子,是临床验证的炎症反应驱动因素,位于影响各种免疫介导疾病的多个信号级联的上游。迄今为止的临床前和临床数据表明,verekitug对TSLP受体具有高度有效的抑制作用,这将转化为差异化的产品特征,包括改善临床结果、大幅延长给药间隔和治疗广泛患者的潜力。他们经验丰富的团队致力于最大限度地发挥verekitug的独特属性,以满足当今护理标准无法满足的患者的大量未满足需求。
发行价格:
17.00
{"stockData":{"symbol":"UPB","market":"US","secType":"STK","nameCN":"UpStream Bio Inc.","latestPrice":11.48,"timestamp":1752264000000,"preClose":11.84,"halted":0,"volume":164986,"hourTrading":{"tag":"盘后","latestPrice":11.48,"preClose":11.48,"latestTime":"17:02 EDT","volume":1006,"amount":11546.68,"timestamp":1752267740132},"delay":0,"floatShares":31301754,"shares":53793703,"eps":-3.404035,"marketStatus":"休市中","change":-0.36,"latestTime":"07-11 16:00:00 EDT","open":11.68,"high":11.85,"low":11.45,"amount":1906406.3005879999,"amplitude":0.033784,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.404035,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1752480000000},"marketStatusCode":7,"adr":0,"listingDate":1728619200000,"exchange":"NASDAQ","adjPreClose":11.84,"postHourTrading":{"tag":"盘后","latestPrice":11.48,"preClose":11.48,"latestTime":"17:02 EDT","volume":1006,"amount":11546.68,"timestamp":1752267740132},"volumeRatio":0.49760736135216277,"impliedVol":0.6714,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/UPB","defaultTab":"news","newsList":[{"id":"2534234101","title":"Upstream Bio, Inc.2025财年第一财季实现净利润-27.27百万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2534234101","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534234101?lang=zh_cn&edition=full","pubTime":"2025-05-12 00:00","pubTimestamp":1746979252,"startTime":"0","endTime":"0","summary":"5月12日,Upstream Bio, Inc.公布财报,公告显示公司2025财年第一财季净利润为-27.27百万美元;其中营业收入为566000.00美元,每股基本收益为-0.51美元。机构评级:截至2025年5月12日,当前有2家机构对Upstream Bio, Inc.目标价做出预测,其中目标均价为55.00美元,其中最低目标价为35.00美元,最高目标价为75.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250512000229a6db2c4c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250512000229a6db2c4c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["UPB"],"gpt_icon":1},{"id":"2486705257","title":"单月超6亿美元,医药企业IPO规模重返疫情前水平","url":"https://stock-news.laohu8.com/highlight/detail?id=2486705257","media":"财通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486705257?lang=zh_cn&edition=full","pubTime":"2024-11-25 17:34","pubTimestamp":1732527240,"startTime":"0","endTime":"0","summary":"今年以来,生物医药领域已经有30家公司IPO上市,累计融资规模超40.49亿美元,其中不乏CG Oncology、Kyverna Therapeutics等IPO规模超3亿美元的公司。在多肽类PTH1R激动剂领域,阿斯利康以总价18亿美元收购AmolytPharma,获得了处于临床3期的PTH1R激动剂eneboparatide,目前该疗法已经获得了FDA快速通道认定,另一家药企AscendisPharma的Yorvipath获得FDA批准上市,用于治疗成人慢性甲状旁腺功能减退。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-11-25/doc-incxhqmk8147031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["GPCR","QLD","BK4020","TQQQ","BK4139","NQmain",".IXIC","OMGA","APGE","AVTE","UPB","BK4561","SYRS","PSQ","BK4082","QID","BK4200","SQQQ","SEPN","BK4539","TSLP","MNQmain","BDMD","BK4007","ASO","GLYC","BK4599","CAMP"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.upstreambio.com","stockEarnings":[{"period":"1week","weight":0.025},{"period":"1month","weight":-0.0171},{"period":"3month","weight":0.5577},{"period":"6month","weight":-0.162},{"period":"1year","weight":-0.3247},{"period":"ytd","weight":-0.3017}],"compareEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.037},{"period":"3month","weight":0.168},{"period":"6month","weight":0.0743},{"period":"1year","weight":0.1207},{"period":"ytd","weight":0.0641}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Upstream Bio, Inc.于2021年4月在特拉华州注册成立。他们是一家临床阶段的生物技术公司,开发炎症性疾病的治疗方法,最初专注于严重的呼吸系统疾病。他们正在开发verekitug,这是目前临床开发中唯一已知的拮抗剂,靶向胸腺间质淋巴细胞生成素(“TSLP”)受体,TSLP是一种细胞因子,是临床验证的炎症反应驱动因素,位于影响各种免疫介导疾病的多个信号级联的上游。迄今为止的临床前和临床数据表明,verekitug对TSLP受体具有高度有效的抑制作用,这将转化为差异化的产品特征,包括改善临床结果、大幅延长给药间隔和治疗广泛患者的潜力。他们经验丰富的团队致力于最大限度地发挥verekitug的独特属性,以满足当今护理标准无法满足的患者的大量未满足需求。","exchange":"NASDAQ","name":"UpStream Bio Inc.","nameEN":"UpStream Bio Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"UpStream Bio Inc.(UPB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供UpStream Bio Inc.(UPB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"UpStream Bio Inc.,UPB,UpStream Bio Inc.股票,UpStream Bio Inc.股票老虎,UpStream Bio Inc.股票老虎国际,UpStream Bio Inc.行情,UpStream Bio Inc.股票行情,UpStream Bio Inc.股价,UpStream Bio Inc.股市,UpStream Bio Inc.股票价格,UpStream Bio Inc.股票交易,UpStream Bio Inc.股票购买,UpStream Bio Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"UpStream Bio Inc.(UPB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供UpStream Bio Inc.(UPB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}